Chiome Bioscience Inc. (4583.T)
JPY 135.0
(4.65%)
JPY 135.0
(4.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.03 Billion JPY | 32.96% |
| 2022 | -1.54 Billion JPY | 4.02% |
| 2021 | -1.6 Billion JPY | 35.84% |
| 2020 | -2.5 Billion JPY | -19.01% |
| 2019 | -2.1 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -811.55 Million JPY | 19.78% |
| 2024 Q1 | -1.01 Billion JPY | 2.21% |
| 2023 FY | -1.03 Billion JPY | 32.96% |
| 2023 Q2 | -947.13 Million JPY | 25.15% |
| 2023 Q1 | -1.26 Billion JPY | 18.0% |
| 2023 Q3 | -1.02 Billion JPY | -8.28% |
| 2023 Q4 | -1.03 Billion JPY | -0.88% |
| 2022 Q3 | -1.4 Billion JPY | 0.0% |
| 2022 Q4 | -1.54 Billion JPY | -9.91% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 239.285% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 8.765% |
| GNI Group Ltd. | -17.93 Billion JPY | 94.231% |
| Linical Co., Ltd. | -4.46 Billion JPY | 76.821% |
| Trans Genic Inc. | -221.16 Million JPY | -367.766% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 76.455% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 78.402% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 172.168% |
| AnGes, Inc. | -3.79 Billion JPY | 72.759% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -145.85% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 104.154% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -107.678% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -121.842% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 61.77% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 45.21% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -5.336% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 69.545% |
| Kidswell Bio Corporation | 343.58 Million JPY | 401.102% |
| PeptiDream Inc. | 3.29 Billion JPY | 131.426% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -6.371% |
| Ribomic Inc. | -2.09 Billion JPY | 50.729% |
| SanBio Company Limited | -3.78 Billion JPY | 72.701% |
| Healios K.K. | -2.19 Billion JPY | 52.76% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -9.493% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 60.576% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 26.993% |
| StemRIM | -8.41 Billion JPY | 87.699% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 77.911% |
| FunPep Company Limited | -1.79 Billion JPY | 42.313% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 51.577% |
| Stella Pharma Corporation | -1.11 Billion JPY | 7.58% |
| TMS Co., Ltd. | -3.44 Billion JPY | 69.984% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 81.378% |
| Cuorips Inc. | -5.56 Billion JPY | 81.396% |
| K Pharma,Inc. | -3.26 Billion JPY | 68.327% |
| Takara Bio Inc. | -32.2 Billion JPY | 96.787% |
| ReproCELL Incorporated | -2.93 Billion JPY | 64.8% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -56.523% |
| StemCell Institute Inc. | -2.83 Billion JPY | 63.53% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 49.933% |
| CellSeed Inc. | -2.01 Billion JPY | 48.582% |